Aduhelm takes another hit as the company pulls its EU marketing application for the Alzheimer's drug.
While treatment trials continue, Biogen's pipeline looks thin.
The company is placing bets on digital health and its multiple sclerosis drug Vumerity to spark future growth.

Search form

You are here